Search Results
Your search for ,aGe matches 8736 pages
Showing 6601 - 6650Strength of Patient-Oncologist Alliance Linked to Willingness to Adhere to Treatment in Young Adults
Among young adults with advanced cancer, developing a strong alliance with their oncologist was associated with greater perceived social support, a greater willingness to adhere to treatment, and greater adherence to oral medication, according to results of a study published in the Journal of...
No Added Benefit from Radiotherapy after Lumpectomy/Tamoxifen in Older Women
Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9343 “confirms and extends the earlier report that in women age ≥ 70 years with clinical stage I, [estrogen receptor (ER)]-positive breast cancer treated with lumpectomy followed by tamoxifen, irradiation adds no significant benefit in...
SIDEBAR: Expect Questions about Preventive Double Mastectomies
For women who are considering prophylactic bilateral mastectomies, “I strongly encourage genetic testing, Todd M. Tuttle, MD, MS, said in an interview with The ASCO Post about the increased interest in preventive double mastectomy following Angelina Jolie’s disclosure that she had the procedure to...
Angelina Jolie's Disclosure of Prophylactic Bilateral Mastectomy: A Positive Example for Women with BRCA Mutations?
Angelina Jolie, in a New York Times article entitled “My Medical Choice,”1 disclosed that having a BRCA1 mutation and an estimated 87% risk of breast cancer, “I decided to be proactive and minimize the risk as much I could. I made a decision to have a preventive double mastectomy.” She was writing...
New Susceptibility Variants for Childhood ALL in Ethnically Diverse Populations
Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and the incidence of the disease varies by ethnicity. Available evidence indicates an inherited predisposition to ALL, but the genetic basis of ALL susceptibility in diverse ancestry has not been examined in detail. Xu and...
FDA Approves Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma
The U.S. Food and Drug Administration has approved lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade). Clinical Trial The approval was based on the results of...
Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was approved by...
Dabrafenib for Unresectable or Metastatic Melanoma with BRAF V600E Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, dabrafenib (Tafinlar) was approved for ...
Improving Treatment and Care for Patients with Primary Brain Cancers
Despite advances in neuroimaging, the development of focused radiation therapy, and more effective chemotherapy, life expectancy for patients with primary malignant tumors of the brain and spinal cord remains stubbornly low at between 15 and 18 months. However, there are significant advances on the ...
Treating Both the Physical and Psychological Symptoms of Cancer
A growing number of people with cancer are being treated on an outpatient basis. At the Herbert Irving Comprehensive Cancer Center of New York-Presbyterian Hospital/Columbia University Medical Center in New York, to ensure that the psychosocial and psychiatric needs of these patients were being...
ASCO Issues Guideline Update and Videos on Fertility Preservation
ASCO recently issued an update to its guideline on fertility preservation for people living with cancer, as well as two videos jointly produced with the LIVESTRONG Foundation. Both the guideline and videos are intended to raise awareness and understanding of this important area of cancer care....
In Memoriam: ASCO Remembers Founding Member Jane Cooke Wright, MD
Earlier this year, ASCO and the oncology community at large lost a true pioneer, mentor, and renowned researcher. It is with great sadness that we mark the passing of Jane Cooke Wright, MD, one of seven founding members of ASCO—the only woman among the founders—and the Society’s first...
Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half
A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...
Study Shows High Concordance of Recurrent Somatic Alterations in Primary and Matched Metastatic NSCLC
In a study reported in Journal of Clinical Oncology, Stéphane Vignot, MD, of Institut National de la Santé et de la Recherche Medicale (INSERM) Unit 981, Paris, and Gustave Roussy Institute, Villejuif, France, and colleagues used next-generation sequencing to identify somatic alterations in...
KRAS Status Not Associated with Survival in Pooled Adjuvant Therapy Trials in Early-stage Lung Cancer
KRAS mutations have been reported in approximately 30% of lung adenocarcinomas. They occur most frequently in codons 12 and 13 in non–small cell lung cancer (NSCLC), and are most common in cancer in smokers and in nonsquamous NSCLC. Some data suggest that KRAS mutation is associated with poorer...
Radiation-sparing Dose-adjusted EPOCH-Rituximab for Primary Mediastinal B-cell Lymphoma
Tumor control is frequently not achieved with standard immunochemotherapy in patients with primary mediastinal B-cell lymphoma, requiring consolidation with mediastinal radiotherapy. However, radiotherapy is associated with serious late adverse effects and is still associated with disease...
FDA Approves New Silicone Gel-filled Breast Implant
The FDA recently approved the MemoryShape Breast Implant for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. The MemoryShape Breast Implants are manufactured by Mentor Worldwide LLC. The FDA’s approval is based on 6 years of data from 955 women...
Expert Point of View: Ann Partridge, MD
This study showed that 10 years of adjuvant tamoxifen reduced the risk of late recurrence in hormone receptor-positive breast cancer, which is a major problem. The study also showed that ‘patience is a virtue’,” stated formal discussant Ann Partridge, MD, Director of the Adult Survivorship Program...
Practice-changing Study Shows Survival Benefit for Antiangiogenesis in Advanced Cervical Cancer
The addition of bevacizumab (Avastin) to chemotherapy prolongs overall survival in women with metastatic cervical cancer compared with chemotherapy alone, according to the results of a randomized phase III study presented at the Plenary Session of the ASCO Annual Meeting.1 Women on the...
It’s Déjà Vu All Over Again
Yogi Berra offered the comment “It’s déjà vu all over again” when he witnessed Mickey Mantle and Roger Maris repeatedly hitting back-to-back home runs in the early 1960s. His pithy remark neatly summarizes my reaction when I read the article, “Dose-Adjusted EPOCH-Rituximab Therapy in Primary...
MSKCC Community Mourns the Death of Trudy Nan Small, MD
Trudy Nan Small, MD, was a pediatric hematologist at Memorial Sloan-Kettering Cancer Center who specialized in the diagnosis and care of children undergoing hematopoietic stem cell transplantation for hematologic malignancies and those with life-threatening genetic disorders of the immune system....
Cognitive Complaints after Breast Cancer Treatment and Neuropsychological Testing
About one in five patients who had completed primary breast cancer treatments but had not started endocrine therapy “had elevated memory and/or executive function complaints that were statistically significantly associated with domain-specific” neuropsychological test performances and depressive...
Driven by the Past
When I was 9 years old, a bout of nausea, vomiting, and abdominal pain sent me to the emergency room. The physicians diagnosed appendicitis and rushed me to the operating room. But what the surgeon found instead was a 10-cm-wide, grade 2, immature teratoma. In 1968, treatment for malignant ovarian...
'Spectacular' Results with Immunotherapies in Melanoma Galvanize the Oncology Community
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Much of the news about immunotherapy ...
SEER Analysis Shows Increased Survival with Surgery and Radiation Therapy in Metastatic Gastric Cancer
A Surveillance, Epidemiology, and End Results (SEER) database analysis reported by Ravi Shridhar, MD, PhD, and colleagues in Cancer indicates that patients receiving surgery and radiation therapy for metastatic gastric cancer have prolonged survival compared with those receiving either alone or...
SIDEBAR: HPV Vaccine Reduces HPV Infection Rate in Girls
A study from the Centers for Disease Control and Prevention (CDC) looking at the prevalence of HPV infections in girls before and after the introduction of the HPV vaccine in 2006 found a significant reduction of 56% in infections among female teenagers aged 14 to 19. About 79 million Americans,...
Study Shows HPV Vaccine Reduced Rate of Infection in Teenage Girls by 56%
A new government study investigating the prevalence of human papillomavirus (HPV) infections in females aged 14 to 59 before and after the introduction in 2006 of the HPV vaccine found that the rate of the HPV infection dropped by 56%, decreasing from 11.5% in 2006 to 5.1% in 2010 among female...
Erlotinib in First-line Treatment of Metastatic NSCLC with EGFR Exon 19 Deletion or Exon 21 (L858R) Substitution
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 14, 2013, erlotinib (Tarceva) was approved for...
Radium-223 Dichloride for Castration-resistant Prostate Cancer with Symptomatic Bone Metastases
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 15, 2013, radium Ra 223 dichloride (Xofigo) was...
Molecular Landscaping of Acute Myeloid Leukemia: Are We Relearning the Past or Informing the Future?
Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease.1 This concept has been supported by more than 4 decades of studies showing distinct outcomes of subsets of patients that differ in age, disease type (primary vs secondary vs therapy-related), and cytogenetic and...
First Positive Trial of Heat Shock Protein 90 Inhibitor in Lung Cancer That Has Progressed after First-line Therapy
The investigational heat shock protein (Hsp)90 inhibitor ganetespib plus docetaxel extended overall survival compared with docetaxel alone as second-line therapy in patients with advanced non–small cell adenocarcinoma of the lung that had progressed on first-line therapy in the randomized phase II...
Second-generation ALK Inhibitor Breakthrough Drug Promising in Early Study for Non–Small Cell Lung Cancer
Encouraging results were seen in a preliminary study of a second-generation ALK inhibitor in advanced ALK-positive non–small cell lung cancer (NSCLC). The drug—dubbed LDK378—achieved tumor shrinkage in almost all patients enrolled in the study, in all mutational subsets, in crizotinib...
Despite a Recurrence, I'm Not Surrendering My Life to Cancer
This is the first time I’m going public with the fact that I have advanced ovarian cancer. I thought I could avoid the fate of my mother and her mother, both of whom died of ovarian cancer in their 50s, and live well past my 60s and even 70s. But at 58, I’ve had to accept that that is not likely. I ...
Encourage Questions about Late Effects of Treatment
Melissa Hudson, MD, of St. Jude Children’s Research Hospital in Memphis, and lead author of a study finding that 98.2% of adult survivors of childhood cancer had a chronic health condition, told The ASCO Post that she hoped that survivors’ awareness of the need for ongoing health monitoring was...
More Than 98% of Childhood Cancer Survivors Have Chronic Health Conditions
More than 98% of adult survivors of childhood cancer in a large clinically evaluated cohort had a chronic health condition, including a substantial number of previously undiagnosed problems that are more likely to occur in an older population. “These findings underscore the importance of ongoing...
Diagnosing and Treating Acute Graft-vs-Host Disease
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that...
Denosumab in Adults and Skeletally Mature Adolescents with Giant Cell Tumor of Bone
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On June 13, 2013, denosumab (Xgeva) was approved for the ...
ACCC Institutes Network to Provide Assistance in Treating Uncommon Cancers
Among the more than 200 types of cancer are those called “forgotten” or “orphan” cancers, with fewer than 40,000 new cases each year. They present treatment challenges in community cancer centers. Because of the low incidence of these diseases, such as chronic myeloid leukemia, acute promyelocytic...
Critically Ill Hematology Patients Admitted to ICU Have Good Survival, Disease Control, and Quality of Life
A large prospective multicenter cohort study in France and Belgium, reported by Elie Azoulay, MD, of Saint-Louis Hospital, Paris, and colleagues from the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique,1 has shown that critically ill patients with hematologic malignancies...
Addition of Brivanib to Cetuximab in Chemotherapy-refractory Metastatic Wild-type KRAS Colorectal Cancer: Key Results
The addition of a combination of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors to chemotherapy has not improved outcome in first-line treatment of advanced colorectal cancer. However, in early-phase evaluation, the addition of the investigational...
New Research Presented in Breast, Gastric, Esophageal Cancers, Melanoma, and Multiple Myeloma, plus Supportive Care
Attendees at the ASCO Annual Meeting are faced with a major challenge of trying to attend as many important sessions as they can over a 4-day period. Our challenge is to feature the major news in The ASCO Post. In addition to our regular comprehensive coverage of key presentations, the following...
Lenalidomide in Relapsed/Progressed Mantle Cell Lymphoma after Two Prior Therapies Including Bortezomib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On June 5, 2013, lenalidomide (Revlimid) was approved...
ASCO Releases Updated Guideline on Interventions for Women at Increased Risk for Breast Cancer
The American Society of Clinical Oncology (ASCO) recently issued a newly updated clinical practice guideline on pharmacologic prevention interventions for premenopausal and postmenopausal women who are at increased risk for breast cancer. Compared to the previous version of the guideline, this...
New Research on Combination Chemotherapy, Prognostic Biomarkers, and PET-guided Radiation Therapy in B-cell Malignancies
The 12th International Conference on Malignant Lymphoma was held June 19-22, 2013, in Lugano, Switzerland. Over 3,000 hematologists, clinical oncologists, pathologists, and leading researchers attended the meeting, which featured new research on B-cell malignancies, follicular lymphoma, as well as...
Shorter Duration of Hormone Therapy Feasible in Localized High-risk Prostate Cancer
Men with localized high-risk prostate cancer treated with adjuvant radiotherapy had similar overall and disease-free survival when treated with 18 months of androgen deprivation therapy vs 36 months of androgen deprivation therapy, the current standard of care in this setting. These results were...
Enzalutamide Monotherapy Highly Active in Patients with Prostate Cancer Who Have Had No Prior Hormone Therapy
Enzalutamide (Xtandi) monotherapy induced striking declines in prostate-specific antigen (PSA) in a majority of patients with hormone-naive prostate cancer in a phase II trial, and this oral agent appears to have little effect on bone mineral density. If these findings are confirmed in a phase III...
Why Is Stem Cell Transplant So Underused in Follicular Lymphoma?
Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma (NHL) in the United States. Of the nearly 70,000 new cases of NHL anticipated in 2013,1 approximately 7,000 to 13,000 (10%–19%) will be follicular lymphoma, by recent estimates.2-5 For many years, the median overall...
Top Five Things Oncologists Need to Know about Cancer in Older Adults
A workforce shortage of geriatricians and other health professionals certified in caring for older patients with cancer is colliding with the aging of the population and the increasing number of older Americans with cancer. After describing factors contributing to these dual challenges, Arti...
ATRA and Arsenic Trioxide May Be Even Better Than ATRA and Chemotherapy in Treating Low-to-Intermediate Risk Acute Promyelocytic Leukemia
All-trans retinoic acid (ATRA) plus arsenic trioxide bested the already high remission rates achieved by ATRA with chemotherapy, the standard of care for acute promyelocytic leukemia, in a phase III multicenter trial among patients with low-to-intermediate risk acute promyelocytic leukemia....
Ridaforolimus Delayed Tumor Progression in Patients with Previously Treated Metastatic Sarcoma
“Ridaforolimus delayed tumor progression to a small statistically significant degree in patients with metastatic sarcoma who experienced benefit with prior chemotherapy,” according to results of an international phase III trial. The large randomized placebo-controlled phase III trial evaluated the...
